Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00058292 · ClinicalTrials.gov registry record · Phase 1
Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
A Phase 1 study of Lymphoma, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
- 3
- Study locations
NCT00058292 is a Phase 1 study of Lymphoma that has completed, run by Northwestern University. The registered enrollment target is 44 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (91% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT00058292, a Phase 1 study of Lymphoma, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
- 3
- Study locations
Study Summary
RATIONALE: Radiolabeled monoclonal antibodies such as yttrium Y90 ibritumomab tiuxetan can locate cancer cells and deliver radioactive cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining yttrium Y90 ibritumomab tiuxetan and chemotherapy with autologous stem cell transplant may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: This phase I trial is studying how well giving yttrium Y90 ibritumomab tiuxetan with high-dose chemotherapy followed by autologous stem cell transplant work in treating patients with relapsed or refractory non-Hodgkin's lymphoma.
Conditions Studied
Interventions
- DRUG Carmustine
- BIOLOGICAL rituximab
- DRUG etoposide
- BIOLOGICAL filgrastim
- DRUG cytarabine
Study Locations (3)
Illinois
- Hematology-Oncology Associates of Illinois - Chicago
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University - Chicago
Minnesota
- Mayo Clinic Cancer Center - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2000-04 |
| Est. Completion | 2009-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00058292
The ClinicalTrials.gov registry entry for NCT00058292 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (91% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Carmustine is the first listed.
NCT00058292 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Illinois, Minnesota.
Frequently Asked Questions
What is clinical trial NCT00058292 about?
NCT00058292 is a clinical study titled "Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma". RATIONALE: Radiolabeled monoclonal antibodies such as yttrium Y90 ibritumomab tiuxetan can locate cancer cells and deliver radioactive cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing...
What is the current status of trial NCT00058292?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2000-04. Estimated completion is 2009-03.
What conditions does trial NCT00058292 study?
This clinical trial studies the following conditions: Lymphoma.
What interventions are being tested in trial NCT00058292?
The interventions under investigation include: Carmustine (DRUG), rituximab (BIOLOGICAL), etoposide (DRUG), filgrastim (BIOLOGICAL), cytarabine (DRUG).
Who is sponsoring clinical trial NCT00058292?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00058292 being conducted?
This trial has 3 study locations across Illinois, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RECRUITING · Phase 1
-
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.